Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle-income Latin American country.

Introduction: Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%-30%. Inhibitor prevalence differs among populations.